Get the Stockscreener App
7.05
6.02%
0.40
After Hours:
7.08
0.03
+0.43%
Karyopharm Therapeutics Inc stock is traded at $7.05, with a volume of 433.17K.
It is up +6.02% in the last 24 hours and down -5.24% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$6.65
Open:
$6.7
24h Volume:
433.17K
Relative Volume:
1.73
Market Cap:
$129.09M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.64
EPS:
-11.016
Net Cash Flow:
$-102.89M
1W Performance:
+18.49%
1M Performance:
-5.24%
6M Performance:
+62.07%
1Y Performance:
-31.49%
1-Day Range:
$6.51
$7.14
1-Week Range:
$5.875
$7.14
52-Week Range:
$3.51
$10.47
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
7.05 | 121.76M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving AverageHere's What Happened - MarketBeat
Can Karyopharm Unlock Xpovio's Growth In 2026 With Pivotal Myelofibrosis Data Ahead? - RTTNews
How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI) - Yahoo Finance
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock By Investing.com - Investing.com UK
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock - Investing.com
RBC Raises Price Target on Karyopharm Therapeutics to $23 From $19, Keeps Outperform Rating - marketscreener.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Spikes: Can Karyopharm Therapeutics Inc disrupt its industryDividend Hike & Verified Entry Point Signals - baoquankhu1.vn
Chart Watch: Will Karyopharm Therapeutics Inc outperform its industry peersJuly 2025 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Options Flow: Will Karyopharm Therapeutics Inc 25K0 stock rise with strong economyWeekly Risk Summary & Safe Entry Zone Tips - Bộ Nội Vụ
Layoff Watch: What margin trends mean for Karyopharm Therapeutics Inc stockWeekly Stock Analysis & Accurate Intraday Trading Signals - Bộ Nội Vụ
Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Establishment Labs Holdings (ESTA) - The Globe and Mail
Karyopharm expects phase 3 trial data in myelofibrosis by March - Investing.com Canada
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Karyopharm Issues Preliminary 2025 Financial Results and Outlook - TipRanks
Karyopharm (KPTI) Anticipates Transformative 2026 with Key Trial Data - GuruFocus
Karyopharm Therapeutics reports preliminary 2025 revenue of $145 mln - TradingView — Track All Markets
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - marketscreener.com
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares - simplywall.st
Is Karyopharm Therapeutics Inc. stock attractive for passive investorsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - ulpravda.ru
Why Karyopharm Therapeutics Inc. (25K0) stock could rally stronglyQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Karyopharm (NASDAQ: KPTI) plans big share authorization increase to fund 2026 trials - Stock Titan
Is Karyopharm Therapeutics Inc. stock supported by innovation pipelineEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
How Karyopharm Therapeutics Inc. stock performs in weak economy2025 Trade Ideas & AI Forecasted Entry and Exit Points - Улправда
Will Karyopharm Therapeutics Inc. (25K0) stock rise with strong economyMarket Growth Summary & Scalable Portfolio Growth Ideas - Улправда
Why Karyopharm Therapeutics Inc. stock attracts global investorsRate Hike & High Accuracy Investment Entry Signals - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investorsPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteTrend Reversal & Daily Chart Pattern Signals - Улправда
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
KPTI (Karyopharm Therapeutics Inc) has impressive results - uspostnews.com
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):